Open Access
Open access
Science, volume 369, issue 6506, pages 1010-1014

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Alina Baum 1
Ying Yan 1
Katrina Koon 1
Krunal Patel 1
Erica Ullman 1
Tammy Huang 1
Wen Yi Lee 1
Glen Farr 1
Seth Pennington 1
Jemmie Cheng 1
Anke Watty 1
Robert BABB 1
Calvin Chen 1
Bojie Zhang 1
Annabel Romero Hernandez 1
Kei Saotome 1
Yi Zhou 1
Sumathi Sivapalasingam 1
David Chien Lye 2
James Logue 3
Robert Haupt 3
Matthew Frieman 3
Gang Chen 1
Neil Stahl 1
George D. Yancopoulos 1
1
 
Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.
2
 
National Centre for Infectious Diseases, Tan Tock Seng Hospital, Yong Loo Lin School of Medicine, Lee Kong Chian School of Medicine, 16 Jalan Tan Tock Seng, Singapore 308442, Singapore.
Publication typeJournal Article
Publication date2020-08-21
Journal: Science
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor56.9
ISSN00368075, 10959203
Multidisciplinary
Abstract
An antibody cocktail against SARS-CoV-2 There is an urgent focus on antibodies that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike and prevent the virus from entering host cells. Hansen et al. generated a large panel of antibodies against the spike protein from humanized mice and recovered patients. From this panel, they identified several neutralizing antibodies, including pairs that do not compete for binding to the receptor binding domain. Baum et al. focused in on four of these antibodies. All four are effective against known spike variants. However, by growing a pseudovirus that expresses the spike in the presence of individual antibodies, the authors were able to select for spike mutants resistant to that antibody. In contrast, escape mutants are not selected when pseudovirus is grown in the presence of pairs of antibodies that either do not compete or only partially compete for binding to the RBD. Such a pair might be used in a therapeutic antibody cocktail. Science, this issue p. 1010, p. 1014 A noncompeting antibody cocktail to SARS-CoV-2 spike protein safeguards against the ability of virus mutations to lead to antibody resistance. Neutralizing antibodies have become an important tool in treating infectious diseases. Recently, two separate approaches yielded successful antibody treatments for Ebola—one from genetically humanized mice and the other from a human survivor. Here, we describe parallel efforts using both humanized mice and convalescent patients to generate antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, which yielded a large collection of fully human antibodies that were characterized for binding, neutralization, and three-dimensional structure. On the basis of these criteria, we selected pairs of highly potent individual antibodies that simultaneously bind the receptor binding domain of the spike protein, thereby providing ideal partners for a therapeutic antibody cocktail that aims to decrease the potential for virus escape mutants that might arise in response to selective pressure from a single-antibody treatment.

Top-30

Citations by journals

5
10
15
20
25
30
35
Cell Reports
34 publications, 3.05%
Nature Communications
34 publications, 3.05%
Frontiers in Immunology
28 publications, 2.52%
Viruses
24 publications, 2.16%
Cell
22 publications, 1.98%
Science
20 publications, 1.8%
Nature
20 publications, 1.8%
iScience
15 publications, 1.35%
Cell Host and Microbe
12 publications, 1.08%
PLoS Pathogens
11 publications, 0.99%
Immunity
11 publications, 0.99%
Vaccines
11 publications, 0.99%
Cell Discovery
11 publications, 0.99%
Signal Transduction and Targeted Therapy
10 publications, 0.9%
International Journal of Molecular Sciences
9 publications, 0.81%
Scientific Reports
9 publications, 0.81%
Computational and Structural Biotechnology Journal
9 publications, 0.81%
Antiviral Research
8 publications, 0.72%
Cell Reports Medicine
8 publications, 0.72%
Proceedings of the National Academy of Sciences of the United States of America
8 publications, 0.72%
Science advances
7 publications, 0.63%
mAbs
6 publications, 0.54%
Antibody Therapeutics
6 publications, 0.54%
Journal of Virology
6 publications, 0.54%
mBio
6 publications, 0.54%
Frontiers in Molecular Biosciences
5 publications, 0.45%
Frontiers in Microbiology
5 publications, 0.45%
Structure
5 publications, 0.45%
Journal of Molecular Biology
5 publications, 0.45%
5
10
15
20
25
30
35

Citations by publishers

50
100
150
200
250
300
Cold Spring Harbor Laboratory
279 publications, 25.07%
Elsevier
226 publications, 20.31%
Springer Nature
175 publications, 15.72%
Multidisciplinary Digital Publishing Institute (MDPI)
76 publications, 6.83%
Frontiers Media S.A.
59 publications, 5.3%
Wiley
38 publications, 3.41%
American Association for the Advancement of Science (AAAS)
36 publications, 3.23%
Oxford University Press
30 publications, 2.7%
American Chemical Society (ACS)
30 publications, 2.7%
American Society for Microbiology
22 publications, 1.98%
Taylor & Francis
20 publications, 1.8%
Public Library of Science (PLoS)
19 publications, 1.71%
Proceedings of the National Academy of Sciences (PNAS)
8 publications, 0.72%
Royal Society of Chemistry (RSC)
6 publications, 0.54%
American Society for Clinical Investigation
5 publications, 0.45%
Future Medicine
5 publications, 0.45%
Rockefeller University Press
5 publications, 0.45%
NEJM Group
3 publications, 0.27%
KeAi Communications Co.
3 publications, 0.27%
American Society for Biochemistry and Molecular Biology
3 publications, 0.27%
EMBO press
3 publications, 0.27%
American Medical Association (AMA)
3 publications, 0.27%
Bentham Science
2 publications, 0.18%
International Union of Crystallography (IUCr)
2 publications, 0.18%
Mary Ann Liebert
2 publications, 0.18%
Portland Press
2 publications, 0.18%
Wolters Kluwer Health
2 publications, 0.18%
Newlands Press Ltd
2 publications, 0.18%
Higher Education Press
2 publications, 0.18%
50
100
150
200
250
300
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Hansen J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail // Science. 2020. Vol. 369. No. 6506. pp. 1010-1014.
GOST all authors (up to 50) Copy
Hansen J., Baum A., Pascal K. E., Russo V., Giordano S., Wloga E., Fulton B. O., Yan Y., Koon K., Patel K., Chung K. M., Hermann A., Ullman E., Cruz J., Rafique A., Huang T., FAIRHURST J. L., Libertiny C., Malbec M., Lee W. Y., Welsh R., Farr G., Pennington S., Deshpande D., Cheng J., Watty A., Bouffard P., BABB R., Levenkova N., Chen C., Zhang B., Romero Hernandez A., Saotome K., Zhou Y., Franklin M., Sivapalasingam S., Lye D. C., Weston S., Logue J., Haupt R., Frieman M., Chen G., Olson W. H., Murphy A. J., Stahl N., Yancopoulos G. D., Kyratsous C. A. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail // Science. 2020. Vol. 369. No. 6506. pp. 1010-1014.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1126/science.abd0827
UR - https://doi.org/10.1126/science.abd0827
TI - Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
T2 - Science
AU - Hansen, Johanna
AU - Baum, Alina
AU - Pascal, Kristen E
AU - Russo, Vincenzo
AU - Giordano, Stephanie
AU - Wloga, Elzbieta
AU - Fulton, Benjamin O
AU - Yan, Ying
AU - Koon, Katrina
AU - Patel, Krunal
AU - Chung, Kyung Min
AU - Hermann, Aynur
AU - Ullman, Erica
AU - Cruz, Jonathan
AU - Rafique, Ashique
AU - Huang, Tammy
AU - FAIRHURST, JEANETTE L.
AU - Libertiny, Christen
AU - Malbec, Marine
AU - Lee, Wen Yi
AU - Welsh, Richard
AU - Farr, Glen
AU - Pennington, Seth
AU - Deshpande, Dipali
AU - Cheng, Jemmie
AU - Watty, Anke
AU - Bouffard, Pascal
AU - BABB, Robert
AU - Levenkova, Natasha
AU - Chen, Calvin
AU - Romero Hernandez, Annabel
AU - Saotome, Kei
AU - Zhou, Yi
AU - Sivapalasingam, Sumathi
AU - Lye, David Chien
AU - Weston, Stuart
AU - Logue, James
AU - Haupt, Robert
AU - Chen, Gang
AU - Olson, William H.
AU - Stahl, Neil
AU - Yancopoulos, George D.
AU - Kyratsous, Christos A.
AU - Zhang, Bojie
AU - Franklin, Matthew
AU - Frieman, Matthew
AU - Murphy, Andrew J.
PY - 2020
DA - 2020/08/21 00:00:00
PB - American Association for the Advancement of Science (AAAS)
SP - 1010-1014
IS - 6506
VL - 369
PMID - 32540901
SN - 0036-8075
SN - 1095-9203
ER -
BibTex |
Cite this
BibTex Copy
@article{2020_Hansen,
author = {Johanna Hansen and Alina Baum and Kristen E Pascal and Vincenzo Russo and Stephanie Giordano and Elzbieta Wloga and Benjamin O Fulton and Ying Yan and Katrina Koon and Krunal Patel and Kyung Min Chung and Aynur Hermann and Erica Ullman and Jonathan Cruz and Ashique Rafique and Tammy Huang and JEANETTE L. FAIRHURST and Christen Libertiny and Marine Malbec and Wen Yi Lee and Richard Welsh and Glen Farr and Seth Pennington and Dipali Deshpande and Jemmie Cheng and Anke Watty and Pascal Bouffard and Robert BABB and Natasha Levenkova and Calvin Chen and Annabel Romero Hernandez and Kei Saotome and Yi Zhou and Sumathi Sivapalasingam and David Chien Lye and Stuart Weston and James Logue and Robert Haupt and Gang Chen and William H. Olson and Neil Stahl and George D. Yancopoulos and Christos A. Kyratsous and Bojie Zhang and Matthew Franklin and Matthew Frieman and Andrew J. Murphy},
title = {Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail},
journal = {Science},
year = {2020},
volume = {369},
publisher = {American Association for the Advancement of Science (AAAS)},
month = {aug},
url = {https://doi.org/10.1126/science.abd0827},
number = {6506},
pages = {1010--1014},
doi = {10.1126/science.abd0827}
}
MLA
Cite this
MLA Copy
Hansen, Johanna, et al. “Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.” Science, vol. 369, no. 6506, Aug. 2020, pp. 1010-1014. https://doi.org/10.1126/science.abd0827.
Found error?